Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers

• Published in: PloS one Vol. 10; no. 4; p. e0123976
• Main Authors: Wu, Shiyang, Liu, Suyan, Liu, Zhiming, Huang, Jiefeng, Pu, Xiaoyu, Li, Jing, Yang, Dinghua, Deng, Haijun, Yang, Ning, Xu, Jiasen
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24.04.2015; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Analysis; Biomarkers, Tumor; Blood; Breast cancer; Cancer; Cancer metastasis; Cancer therapies; Carcinoma; Case-Control Studies; Cell adhesion & migration; Cell Line, Tumor; Classification; Colon; Colon cancer; Colorectal cancer; Deoxyribonucleic acid; DNA; Epithelial-Mesenchymal Transition - genetics; Female; Gastric cancer; Hep G2 Cells; Humans; Hybridization; In Situ Hybridization; Leukocytes - metabolism; Liver; Liver cancer; Lung cancer; Lung diseases; Male; Markers; Medical prognosis; Mesenchyme; Metastases; Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms - diagnosis; Neoplasms - genetics; Neoplastic Cells, Circulating - metabolism; Neoplastic Cells, Circulating - pathology; Non-small cell lung cancer; Non-small cell lung carcinoma; Patients; Phenotypes; Prostate; Reproducibility of Results; Ribonucleic acid; RNA; Science; Stem cells; Studies; Subpopulations; Surgery; Tumor cells; Tumors; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0123976

In cancer, epithelial-mesenchymal transition (EMT) is associated with metastasis. Characterizing EMT phenotypes in circulating tumor cells (CTCs) has been challenging because epithelial marker-based methods have typically been used for the isolation and detection of CTCs from blood samples. The aim of this study was to use the optimized CanPatrol CTC enrichment technique to classify CTCs using EMT markers in different types of cancers. The first step of this technique was to isolate CTCs via a filter-based method; then, an RNA in situ hybridization (RNA-ISH) method based on the branched DNA signal amplification technology was used to classify the CTCs according to EMT markers. Our results indicated that the efficiency of tumor cell recovery with this technique was at least 80%. When compared with the non-optimized method, the new method was more sensitive and more CTCs were detected in the 5-ml blood samples. To further validate the new method, 164 blood samples from patients with liver, nasopharyngeal, breast, colon, gastric cancer, or non-small-cell lung cancer (NSCLC) were collected for CTC isolation and characterization. CTCs were detected in 107 (65%) of 164 blood samples, and three CTC subpopulations were identified using EMT markers, including epithelial CTCs, biophenotypic epithelial/mesenchymal CTCs, and mesenchymal CTCs. Compared with the earlier stages of cancer, mesenchymal CTCs were more commonly found in patients in the metastatic stages of the disease in different types of cancers. Circulating tumor microemboli (CTM) with a mesenchymal phenotype were also detected in the metastatic stages of cancer. Classifying CTCs by EMT markers helps to identify the more aggressive CTC subpopulation and provides useful evidence for determining an appropriate clinical approach. This method is suitable for a broad range of carcinomas.